Trial Profile
A Randomized, Double-Blind, Controlled, Single-Dose, 3-Treatment, 3-Period, 6-Sequence Crossover Study to Compare Exposure and Activity of SAR341402 to NovoRapid and NovoLog Using the Euglycemic Clamp Technique, in Subjects With Type 1 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Sanofi
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 03 Jul 2017 New trial record